Encompass Health Co. (NYSE:EHC) Shares Sold by Leeward Investments LLC MA

Leeward Investments LLC MA lowered its stake in shares of Encompass Health Co. (NYSE:EHC) by 0.5% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 550,066 shares of the company’s stock after selling 3,042 shares during the quarter. Encompass Health comprises approximately 2.0% of Leeward Investments LLC MA’s investment portfolio, making the stock its 2nd largest holding. Leeward Investments LLC MA owned about 0.55% of Encompass Health worth $45,424,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently modified their holdings of the stock. Acadian Asset Management LLC acquired a new stake in Encompass Health during the 3rd quarter worth about $111,000. Stifel Financial Corp boosted its holdings in shares of Encompass Health by 1.7% in the 3rd quarter. Stifel Financial Corp now owns 48,478 shares of the company’s stock valued at $3,256,000 after acquiring an additional 792 shares during the last quarter. Federated Hermes Inc. increased its stake in shares of Encompass Health by 13.3% in the third quarter. Federated Hermes Inc. now owns 15,400 shares of the company’s stock worth $1,034,000 after acquiring an additional 1,803 shares during the period. Treasurer of the State of North Carolina raised its holdings in shares of Encompass Health by 0.5% during the third quarter. Treasurer of the State of North Carolina now owns 48,339 shares of the company’s stock worth $3,246,000 after purchasing an additional 231 shares during the last quarter. Finally, Synovus Financial Corp lifted its position in Encompass Health by 8.1% during the third quarter. Synovus Financial Corp now owns 6,459 shares of the company’s stock valued at $434,000 after purchasing an additional 482 shares during the period. 97.25% of the stock is owned by hedge funds and other institutional investors.

Encompass Health Price Performance

Encompass Health stock traded up $0.47 during trading on Thursday, reaching $86.04. The company had a trading volume of 547,774 shares, compared to its average volume of 607,434. The firm has a market capitalization of $8.66 billion, a PE ratio of 23.25, a price-to-earnings-growth ratio of 1.33 and a beta of 0.89. The firm’s 50-day simple moving average is $85.07 and its 200 day simple moving average is $77.97. The company has a debt-to-equity ratio of 1.14, a quick ratio of 1.37 and a current ratio of 1.37. Encompass Health Co. has a 1-year low of $57.55 and a 1-year high of $87.94.

Encompass Health (NYSE:EHC) last announced its earnings results on Wednesday, April 24th. The company reported $1.12 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.93 by $0.19. Encompass Health had a net margin of 7.60% and a return on equity of 18.01%. The business had revenue of $1.32 billion for the quarter, compared to analyst estimates of $1.27 billion. During the same quarter last year, the business earned $0.88 earnings per share. The company’s revenue for the quarter was up 13.4% compared to the same quarter last year. As a group, equities research analysts anticipate that Encompass Health Co. will post 4.1 earnings per share for the current fiscal year.

Encompass Health Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, July 15th. Stockholders of record on Monday, July 1st will be given a $0.15 dividend. The ex-dividend date of this dividend is Monday, July 1st. This represents a $0.60 annualized dividend and a dividend yield of 0.70%. Encompass Health’s dividend payout ratio (DPR) is presently 16.22%.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on the company. Raymond James reiterated a “strong-buy” rating and set a $95.00 price objective (up previously from $85.00) on shares of Encompass Health in a research note on Friday, April 26th. Stephens reiterated an “overweight” rating and set a $94.00 price target on shares of Encompass Health in a research report on Wednesday, June 5th. Mizuho upped their price objective on Encompass Health from $93.00 to $95.00 and gave the stock a “buy” rating in a research report on Thursday, April 25th. Barclays raised their price objective on shares of Encompass Health from $101.00 to $108.00 and gave the stock an “overweight” rating in a research note on Thursday, April 25th. Finally, Royal Bank of Canada increased their price target on shares of Encompass Health from $83.00 to $95.00 and gave the stock an “outperform” rating in a report on Wednesday, May 22nd. Eight equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Buy” and a consensus target price of $93.29.

Insider Transactions at Encompass Health

In related news, insider Elissa Joy Charbonneau sold 10,000 shares of the stock in a transaction on Friday, May 24th. The stock was sold at an average price of $85.02, for a total value of $850,200.00. Following the completion of the transaction, the insider now directly owns 18,594 shares of the company’s stock, valued at approximately $1,580,861.88. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. In related news, CEO Mark J. Tarr sold 44,976 shares of the stock in a transaction that occurred on Tuesday, April 30th. The stock was sold at an average price of $83.27, for a total value of $3,745,151.52. Following the completion of the sale, the chief executive officer now owns 554,098 shares of the company’s stock, valued at $46,139,740.46. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, insider Elissa Joy Charbonneau sold 10,000 shares of the business’s stock in a transaction on Friday, May 24th. The stock was sold at an average price of $85.02, for a total value of $850,200.00. Following the transaction, the insider now directly owns 18,594 shares in the company, valued at approximately $1,580,861.88. The disclosure for this sale can be found here. Insiders have sold 69,519 shares of company stock valued at $5,816,091 over the last ninety days. Insiders own 2.10% of the company’s stock.

Encompass Health Profile

Encompass Health Corporation provides post-acute healthcare services in the United States and Puerto Rico. It owns and operates inpatient rehabilitation hospitals that provide medical, nursing, therapy, and ancillary services. The company provides specialized rehabilitative treatment on an inpatient basis to patients who have experienced physical or cognitive disabilities or injuries due to medical conditions, such as strokes, hip fractures, and various debilitating neurological conditions.